ArticleBiochemistry2020
Depurination of Colibactin-Derived Interstrand Cross-Links.
Article in Biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Chemiluminescent Probes Allow for the Rapid Identification of Colibactin-Producing Bacteria.JACS Au · 2026Article
- Chemiluminescent probes allow for the rapid identification of colibactin-producing bacteria.bioRxiv : the preprint server for biology · 2026Article
- The specificity and structure of DNA cross-linking by the gut bacterial genotoxin colibactin.Science (New York, N.Y.) · 2025Article
- The Fanconi anemia pathway repairs colibactin-induced DNA interstrand cross-links.Nature communications · 2025Article
- The specificity and structure of DNA crosslinking by the gut bacterial genotoxin colibactin.bioRxiv : the preprint server for biology · 2025Article
- The microbial landscape of colorectal cancer.Nature reviews. Microbiology · 2024Review
- Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.Cell reports. Medicine · 2024Article
- The Role of Microbiota-Derived Metabolites in Colorectal Cancer.International journal of molecular sciences · 2023Review
- Delivery, structure, and function of bacterial genotoxins.Virulence · 2022Review
- Mechanism-based design of agents that selectively target drug-resistant glioma.Science (New York, N.Y.) · 2022Article
- Reply to Dubbert and von Bünau, "A Probiotic Friend".mSphere · 2021Article
- Tackling the Threat of Cancer Due to Pathobionts Producing Colibactin: Is Mesalamine the Magic Bullet?Toxins · 2021Review
- Cyclomodulins and Hemolysis inLife (Basel, Switzerland) · 2021Article
- Review
- Genomic aberrations after short-term exposure to colibactin-producing E. coli transform primary colon epithelial cells.Nature communications · 2021Article
- The Polyphosphate Kinase of Escherichia coli Is Required for Full Production of the Genotoxin Colibactin.mSphere · 2020Article
- Colibactin DNA-damage signature indicates mutational impact in colorectal cancer.Nature medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Colibactin is a genotoxic gut microbiome metabolite long suspected of playing an etiological role in colorectal cancer. Evidence suggests that colibactin forms DNA interstrand cross-links (ICLs) in eukaryotic cells and activates ICL repair pathways, leading to the production of ICL-dependent DNA double-strand breaks (DSBs). Here we show that colibactin ICLs can evolve directly to DNA DSBs. Using the topology of supercoiled plasmid DNA as a proxy for alkylation adduct stability, we find that colibactin-derived ICLs are unstable toward depurination and elimination of the 3' phosphate. This ICL degradation pathway leads progressively to single strand breaks (SSBs) and subsequently DSBs. The spontaneous conversion of ICLs to DSBs is consistent with the finding that nonhomologous end joining repair-deficient cells are sensitized to colibactin-producing bacteria. The results herein refine our understanding of colibactin-derived DNA damage and underscore the complexities underlying the DSB phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.